← back to search

Maurizio Zangari

University of Arkansas for Medical Sciences · US
Area of research
Hematology · Oncology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Cancer Treatment and Pharmacology, and Peptidase Inhibition and Analysis.
h-index
70
citations
19,337
works
514
NIH funding
primary concept
email

Recent publications

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Blood Cancer Journal 2024cited by 93position: middledoi
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
Nature Communications 2023cited by 35position: middledoi
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
Nature Communications 2022cited by 73position: middledoi
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
Blood Advances 2022cited by 53position: middledoi
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
PLoS Medicine 2020cited by 74position: middledoi
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry
Blood Advances 2020cited by 31position: middledoi
Visualizing collagen proteolysis by peptide hybridization: From 3D cell culture to in vivo imaging
Biomaterials 2018cited by 84position: middledoi
Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma
Blood 2017cited by 247position: middledoi
NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers
Cancer Cell 2013cited by 298position: middledoi
Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?
Blood Coagulation & Fibrinolysis 2013cited by 28position: firstdoi
A Meta-Analysis Of Genome-Wide Association Studies Of Multiple Myeloma In Cases and Controls Of European Origin Identifies a Risk Locus In 12q23.1
Blood 2013cited by 0position: middledoi
Impact of bortezomib on bone health in myeloma: A review of current evidence
Cancer Treatment Reviews 2012cited by 48position: firstdoi
Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high‐dose melphalan in patients with multiple myeloma
European Journal Of Haematology 2012cited by 12position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Frits van Rhee · Winthrop Rockefeller Foundation4 papers (2017–2024)Sharmilan Thanendrarajan · University of Arkansas for Medical Sciences4 papers (2017–2024)Carolina Schinke · University of Arkansas for Medical Sciences4 papers (2017–2024)Gareth J. Morgan · Amyloidosis Foundation3 papers (2017–2022)Leo Rasche · Universitätsklinikum Würzburg3 papers (2017–2022)Faith E. Davies · New York University Florence3 papers (2017–2022)Niels Weinhold · Sylvester Comprehensive Cancer Center3 papers (2017–2022)Shayu Deshpande · University of Arkansas for Medical Sciences2 papers (2022–2022)Bart Barlogie · University of Arkansas for Medical Sciences2 papers (2017–2022)Fenghuang Zhan · Cancer Research Center2 papers (2012–2013)Guido Tricot · Cancer Research Center2 papers (2012–2013)Michael Bauer · University of Arkansas for Medical Sciences2 papers (2022–2022)Tamara Berno · University of Padua2 papers (2012–2013)Alexandra M. Poos · German Cancer Research Center2 papers (2022–2022)Brian A. Walker · University of Miami2 papers (2017–2022)Samer Al Hadidi · Arkansas Department of Agriculture2 papers (2022–2024)Sabina Świerczek · Danbury Hospital1 papers (2013–2013)Kari Hemminki · Lund University1 papers (2017–2017)Cody Ashby · University of Arkansas for Medical Sciences1 papers (2022–2022)Francesco Maura · Palmetto General Hospital1 papers (2022–2022)